news Photobiomodulation therapy may improve future burn treatments 10 August 2021 | By Anna Begley (Drug Target Review) Photobiomodulation therapy was shown to heal burn injuries faster by triggering the growth protein TGF-beta 1 in mice, potentially improving treatments.
news Triple drug combination shows promise for pancreatic cancer treatment 10 August 2021 | By Anna Begley (Drug Target Review) MIT researchers have shown that a combination of three drugs can eliminate pancreatic tumours in mice, possibly leading to new therapies.
news Key hallmark of ALS is successfully reversed in laboratory 9 August 2021 | By Anna Begley (Drug Target Review) Scientists demonstrated how to reverse the incorrect localisation of three RNA-binding proteins in ALS, potentially leading to treatments.
news Licensed drug may reduce COVID-19 infection by 70 percent 6 August 2021 | By Anna Begley (Drug Target Review) Fenofibrate and its active form, fenofibric acid, have been shown to significantly reduce COVID-19 infection in human cells.
news Therapeutic target for aggressive cancers discovered through CRISPR 5 August 2021 | By Anna Begley (Drug Target Review) The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
news CRISPR-Cas9 used to prevent Fuchs’ corneal dystrophy in mice 4 August 2021 | By Anna Begley (Drug Target Review) Scientists have shown that start codon disruption with CRISPR-Cas9 gene editing can prevent Fuchs’ corneal dystrophy in mouse models.
news Removal of RNA-binding protein improves leukaemia survival 30 July 2021 | By Anna Begley (Drug Target Review) Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
news Farnesol shows potential to prevent and treat Parkinson’s disease 29 July 2021 | By Anna Begley (Drug Target Review) Researchers have added to evidence that farnesol prevents and reverses brain damage linked to Parkinson’s disease in mouse models.
news New “atlas” charts how antibodies attack COVID-19 Spike variants 26 July 2021 | By Anna Begley (Drug Target Review) A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
news Algorithm helps find best drug targets for all COVID-19 variants 23 July 2021 | By Anna Begley (Drug Target Review) A new computer algorithm has identified highly conserved sequences in viral proteins that could make the best drug targets for COVID-19.
news Treg cells could be answer to multiple sclerosis treatments, say scientists 21 July 2021 | By Anna Begley (Drug Target Review) New research has shown that the protein Piezo 1 prevented Treg cells from controlling the effects of inflammation in a multiple sclerosis mouse model.
article Recognition of phosphohistidine-containing peptides by antibodies 16 July 2021 | By Dr Rajasree Kalagiri (Salk Institute), Professor Tony Hunter (Salk Institute) In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
news Therapeutic target discovery could improve breast cancer treatments 14 July 2021 | By Anna Begley (Drug Target Review) Research by a team in Canada reveals a promising therapeutic target to counter HER2-positive breast cancer.
news “Woman-controlled, on-demand” contraceptive product developed in US 13 July 2021 | By Anna Begley (Drug Target Review) US researchers have developed an antisperm monoclonal antibody that could become a safe and effective birth control method.
article How engineered RNA binding proteins delivered in vivo by gene therapy could treat myotonic dystrophy 13 July 2021 | By Dr Jim Burns (Locanabio) In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
